September 6, 2022
South San Francisco, Calif. – September 6, 2022 – Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round. New investors Softbank Vision Fund 2, Bristol-Myers Squibb Company, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street, and others joined existing investors the Parker Institute for Cancer Immunotherapy (PICI), Westlake Village BioPartners, the University of California, San Francisco (UCSF) Foundation Investment Company, Euclidean Capital, Waycross Ventures, and Kleiner Perkins, in supporting the oversubscribed round. Proceeds from the financing will help the company expand its programmable cell therapy research activities and grow its pipeline of therapeutic candidates for solid tumor malignancies across a range of cancer indications. FLG Partner Kenton Chow assisted.
Full press release is here (see NEWS).